|   | |
| Clinical data | |
|---|---|
| Other names | 4-OH-DBT; 4-Hydroxy-N,N-dibutyltryptamine | 
| Routes of administration | Oral [1] | 
| Drug class | Serotonergic psychedelic; Hallucinogen | 
| ATC code | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | 
 | 
| UNII | |
| Chemical and physical data | |
| Formula | C18H28N2O | 
| Molar mass | 288.435 g·mol−1 | 
| 3D model (JSmol) | |
| Melting point | 74 to 75 °C (165 to 167 °F) | 
| 
 | |
| 
 | |
|  N  Y  (what is this?)    (verify) | |
4-HO-DBT, also known as 4-hydroxy-N,N-dibutyltryptamine, is a psychedelic drug of the tryptamine family related to psilocin (4-HO-DMT). [1] It is taken orally. [1]
4-HO-DBT was first made by the chemist Alexander Shulgin and reported in his book TiHKAL. [1] Shulgin reported a dosage of 20 mg orally to be without effects. [1] However, this compound has subsequently been sold as a "research chemical" and anecdotal reports suggest that at higher doses 4-HO-DBT is indeed an active hallucinogen, although somewhat weaker than other similar tryptamine derivatives.[ citation needed ]
4-HO-DBT is found either as its crystalline hydrochloride salt or as an oily or crystalline base.
The chemical synthesis of 4-HO-DBT has been described. [1]
Several different isomers of 4-HO-DBT could be made (see dibutyltryptamine for a fuller discussion), but of these only the isobutyl isomer 4-HO-DiBT was synthesized by Alexander Shulgin (melting point 152 to 154 °C) and was also found to be inactive at a 20 mg dose. [1]
4-HO-DBT was first described in the scientific literature by David Repke and colleagues in 1977. [2]
| Tryptamines | 
 | 
|---|---|
| 4-Hydroxytryptamines and esters/ethers | 
 | 
| 5-Hydroxy- and 5-methoxytryptamines | 
 | 
| N-Acetyltryptamines | 
 | 
| α-Alkyltryptamines | 
 
 
 | 
| Cyclized tryptamines | 
 | 
| Isotryptamines | |
| Related compounds | 
 |